Genezen Invests in New CGMP Lentiviral Vector Production Facility

Contract development and manufacturing organization (CDMO) Genezen Laboratories has broken ground on a new current good manufacturing practice (CGMP)-compliant lentiviral vector production facility.

According to a June 24, 2021 press release, the first phase of the build will incorporate the construction of a 25,000-ft² site that will include a process development lab expansion. Completion of the first phase is anticipated in Autumn 2021 with the remaining build out expected to be completed early on in 2022. The new facility is being funded by a majority investment from Ampersand Capital Partners.

“The cell and gene therapy sector is evolving rapidly, and there’s growing demand for capacity and expertise. Building on recognized expertise in lentiviral and retroviral vector platforms, and leveraging the CDMO experience of our investor Ampersand, we are investing heavily to meet this need now, and in the future,” said Bill Vincent, chairman and CEO of Genezen, in the press release. “Our new facility will support clients with the latest technologies as they develop and deliver life-changing therapeutics to patients.”

“I am confident that our partnership will help Genezen to better serve its customers as the company builds out its infrastructure and service offering, to complement the deep expertise of its people,” added David Anderson, general partner at Ampersand, in the press release. “We believe that Genezen will fast become a market leader in CGMP manufacturing of lentiviral vectors for the cell and gene therapy sector—it’s an incredibly exciting prospect in a revolutionary healthcare market that is set to grow for years to come.”

Source: Genezen